Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Trial details

Who runs it

Jazz Pharmaceuticals

Trial code

NCT06282575EU 2023-508219-21-00

Record updated

28 October 2026

Original description

The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.Read full original descriptionShow less

An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer

The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.

Inclusion: Histologically- or cytologically-confirmed Biliary Tract Cancer (BTC), including Gallbladder Cancer (GBC), Intrahepatic Cholangiocarcinoma (ICC), or Extrahepatic Cholangiocarcinoma (ECC); Locally advanced unresectable or metastatic BTC and not eligible for curative resection, transplantation, or ablative therapies; Received no more than 2 cycles of systemic therapy which is limited to Cisplatin and Gemcitabine (CisGem) with or without a PD-1/L1 inhibitor (physician's choice of durvalumab or pembrolizumab, where approved under local regulations) for advanced unresectable or metastatic disease; HER2-positive disease (defined as IHC 3+; or IHC 2+/ ISH+) by IHC and in situ Hybridization (ISH) assay (in participants with IHC 2+ tumors) at a central laboratory on new biopsy tissue or archival tissue from the most recent biopsy; Assessable (measurable or non-measurable) disease as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), per investigator assessment; Male or female ≥ 18 years or age (or the legal age of adulthood per country-specific regulations); Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Adequate organ function; Females of childbearing potential must have a negative pregnancy test result; Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of birth control.

Exclusion: Prior treatment with a HER2-targeted agent; Prior treatment with checkpoint inhibitors, other than durvalumab or pembrolizumab; Use of systemic corticosteroids; Active or prior autoimmune inflammatory conditions; The following BTC histologic subtypes are excluded: small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology, and mucinous cystic neoplasms detected in the biliary tract region; Severe chronic or active infections; History of allogeneic organ transplantation; History of interstitial lung disease or non-infectious pneumonitis; Brain metastases; Participation in another clinical trial with an investigational medicinal product within the last 3 months; Females who are breastfeeding; Any other medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures; Use of phenytoin.

ClinicalTrials.gov NCT06282575 · EU CTIS 2023-508219-21-00